China's Most Valuable Company Faces First Earnings Test | The China Show | 8/28/2026

Watch on YouTube ↗  |  August 28, 2026 at 06:07  |  1:32:33  |  Bloomberg Markets
Speakers
Raphael Zagury — CEO, 21 Capital
Xuefeng Yu — Chairman and CEO, CanSino Biologics
May Yuan — Head of Asia Financials Research, UBS Investment Bank
Julie — Deputy Head of Investment Banking, BOC International
Danielle DiMartino Booth — CEO, QI Research
Charlotte Yang — Asia Equities Reporter, Bloomberg

Summary

The show covers the latest market movements in Greater China, with a focus on upcoming earnings reports from major companies like BYD and CXMT. Key discussions include the impact of macroeconomic events on Bitcoin's price, the growth prospects of CanSino Biologics, and the attractiveness of large Chinese banks for dividend investors. The program also highlights the increasing issuance of Dim Sum and Panda bonds as alternatives to US dollar debt.

  • Investors await Kevin Warsh's Jackson Hole speech for clarity on the Fed's reaction function.
  • Bitcoin surges past $80,000, driven by institutional adoption and its appeal as a predictable reserve asset.
  • CanSino Biologics reports strong revenue growth, fueled by international vaccine sales and its mRNA cancer pipeline.
  • UBS recommends large Chinese banks for their sustainable dividend yields exceeding 5%.
  • Dim Sum and Panda bond issuance rises as issuers seek cheaper and less volatile funding compared to US debt.
  • BYD's upcoming earnings will test its ability to maintain profit margins through overseas sales amidst domestic competition.
Ideas
Raphael Zagury CEO, 21 Capital 31:42
Bitcoin's predictable monetary policy justifies a premium.
Bitcoin is the world's best savings technology with an extremely predictable monetary issuance, and it should trade at a premium as institutional adoption grows and macro uncertainty highlights its value as a reserve asset.
BTC HIGH
Xuefeng Yu Chairman and CEO, CanSino Biologics 49:08
Vaccine sales and mRNA pipeline drive growth.
CanSino Biologics is transitioning to profitability with strong revenue growth driven by its meningococcal and pneumococcal conjugate vaccines, significant international market expansion, and a promising mRNA pipeline for cancer therapeutics.
CANSF HIGH
May Yuan Head of Asia Financials Research, UBS Investment Bank 71:36
Large Chinese banks offer sustainable high dividends.
Large Chinese banks are attractive investments because they offer sustainable dividend yields of over 5%, supported by stabilizing net interest margins and a return to positive revenue growth.
KBA HIGH
Julie Deputy Head of Investment Banking, BOC International 72:53
Dim sum bonds offer cheaper funding options.
Dim sum and Panda bonds are seeing strong issuance demand because their yields are relatively low and less volatile compared to US dollar debt, offering cheaper funding and diversification for issuers.
Dim Sum Bonds Panda Bonds MED
Up Next
46:03
Hormuz Oil Flows Recover as Supply Fears Ease | Horizons Middle East & Africa 8/28/2026
Bloomberg Markets · Aug 28
1:16
Judge Lifts US Ban on Anthropic's Use for Federal Agencies
Bloomberg Markets · Aug 28
25:41
[Urgent Market Update] Samsung Electronics, SK Hynix Stock Price Decline.. NVIDIA Gave a Clear Answer! Don't Be Scared by Semiconductor Stock Correction / "Why I Don't Worry About Semiconductor Tariffs" | Park Geun-hyung, Department Head
815 Money Talk (815머니톡) · Aug 28
1:12:05
Traders Focus on Jackson Hole, Fed Outlook | The Asia Trade 8/28/2026
Bloomberg Markets · Aug 28
6:12:36
[26.08.28 Morning Broadcast Full View] New York Stock Market Closes Up Amid NVIDIA's 9% Surge...Now Eyes on Jackson Hole?!
3PRO TV (삼프로TV) · Aug 28

This Bloomberg Markets video, published August 28, 2026, features Raphael Zagury, Xuefeng Yu, May Yuan, Julie discussing BTC, CANSF, KBA, Dim Sum Bonds, Panda Bonds. 4 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Raphael Zagury, Xuefeng Yu, May Yuan, Julie  · Tickers: BTC, CANSF, KBA, Dim Sum Bonds, Panda Bonds